Lupus nephritis is associated with more corticosteroid-associated organ damage but less corticosteroid non-associated organ damage

Lupus

Volumn 26, Issue 6, 2017, Pages 598-605

  Joo, Y B ^a   Won, S ^b   Choi, C B ^b,c   Bae, S C ^b,c  

^a The Catholic University of Korea   (South Korea)

^b Clinical Research Center for Rheumatoid Arthritis   (South Korea)

^c Hanyang University Hospital for Rheumatic Diseases   (South Korea)

Author keywords

corticosteroid; lupus nephritis; organ damage; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISOLONE;

ADULT; ALOPECIA; ARTHRITIS; ARTICLE; AVASCULAR NECROSIS; CATARACT; CHRONIC DISEASE; CHRONIC PANCREATITIS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE DURATION; DRUG PULSE THERAPY; EROSION; FEMALE; FRACTURE; GASTROINTESTINAL STRICTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGONADISM; INTESTINE INFARCTION; LUNG INFARCTION; LUNG INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MESENTERIC INSUFFICIENCY; MESENTERY DISEASE; OBSERVATIONAL STUDY; ORGAN INJURY; OSTEOPOROSIS; PERITONITIS; PLEURAL FIBROSIS; PREMATURE GONADAL FAILURE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; PULMONARY HYPERTENSION; SCAR FORMATION; SHRINKING LUNG; SKIN ULCER; STANDARDIZED MORTALITY RATIO; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; CHEMICALLY INDUCED; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MORTALITY; ODDS RATIO; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; FEMALE; HUMANS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; ODDS RATIO; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85018341722     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203316671813     Document Type: Article

References (27)

1. Sutton EJ, Davidson JE, Bruce IN,. The systemic lupus international collaborating clinics (SLICC) damage index: A systematic literature review. Semin Arthritis Rheum 2013; 43: 352-361.
2. Ugarte-Gil MF, Acevedo-Vasquez E, Alarcon GS, et al. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: Data from a multiethnic Latin American cohort. Ann Rheum Dis 2015; 74: 1019-1023.
3. Mak A, Isenberg DA, Lau CS,. Global trends, potential mechanisms and early detection of organ damage in SLE. Nat Rev Rheumatol 2013; 9: 301-310.
4. Goncalves MJ, Sousa S, Ines LS, et al. Characterization of damage in Portuguese lupus patients: Analysis of a national lupus registry. Lupus 2015; 24: 256-262.
5. Rabbani MA, Habib HB, Islam M, et al. Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients. Lupus 2009; 18: 848-855.
6. Hiraki LT, Benseler SM, Tyrrell PN, et al. Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol 2009; 36: 2539-2546.
7. Joo YB, Bae SC,. Assessment of clinical manifestations, disease activity and organ damage in 996 Korean patients with systemic lupus erythematosus: Comparison with other Asian populations. Int J Rheum Dis 2015; 18: 117-128.
8. Ibanez D, Urowitz MB, Gladman DD,. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 2003; 30: 1977-1982.
9. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
10. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725-1725.
11. Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1955-1959.
12. Kim YJ, Shim JS, Choi CB, et al. Mortality and incidence of malignancy in Korean patients with rheumatoid arthritis. J Rheumatol 2012; 39: 226-232.
13. Al Sawah S, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. Lupus Sci Med 2015; 2: e000066-e000066.
14. Ibanez D, Gladman DD, Urowitz MB,. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005; 32: 824-827.
15. Thamer M, Hernan MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009; 36: 560-564.
16. Stoll T, Sutcliffe N, Mach J, et al. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus-a 5-yr prospective study. Rheumatology (Oxford) 2004; 43: 1039-1044.
17. Livingston B, Bonner A, Pope J,. Differences in autoantibody profiles and disease activity and damage scores between childhood- and adult-onset systemic lupus erythematosus: A meta-analysis. Semin Arthritis Rheum 2012; 42: 271-280.
18. Uziel Y, Gorodnitski N, Mukamel M, et al. Outcome of a national Israeli cohort of pediatric systemic lupus erythematosus. Lupus 2007; 16: 142-146.
19. Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: Prevalence and outcomes. Ann Rheum Dis 2015; 74: 2117-2122.
20. Urowitz MB, Gladman DD, Ibanez D, et al. Damage Due to glucocorticoids in a multicentre SLE inception cohort [abstract]. Arthritis Rheum 2009; 60 (Suppl. 10): 280-280.
21. Kirwan JR,. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333: 142-146.
22. Nakashima T, Sasaki H, Tsuboi M, et al. Inhibitory effect of glucocorticoid for osteoblast apoptosis induced by activated peripheral blood mononuclear cells. Endocrinology 1998; 139: 2032-2040.
23. Hofkens W, Grevers LC, Walgreen B, et al. Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis. J Control Release 2011; 152: 363-369.
24. Ruiz-Arruza I, Barbosa C, Ugarte A, et al. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev 2015; 14: 875-879.
25. Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 1801-1808.
26. Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, et al. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2014; 53: 1470-1476.
27. Ruiz-Irastorza G, Danza A, Perales I, et al. Prednisone in lupus nephritis: How much is enough? Autoimmun Rev 2014; 13: 206-214.